Navigation Links
Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
Date:4/1/2011

gated hyperbilirubinemia.  Average alanine aminotransferase (ALT) improved in all BI 201335 groups compared to placebo, and there was no excess anemia reported in the study.  Across BI 201335 treatment groups, 4 to 12 percent of patients discontinued BI 201335 due to AEs.  

(Oral abstract #66) SILEN-C2: Sustained Virologic Response and Safety of BI 201335 Combined with Peginterferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Patients with Non-Response to PegIFN/RBVThe SILEN-C2 study evaluated the virological response and safety of different doses of BI 201335 in treatment-experienced patients who did not respond to at least 12 weeks of prior treatment with PegIFN/RBV. This patient population is particularly difficult to treat, as patients who have not responded to PegIFN/RBV alone have low response rates to additional treatments. The trial did not include patients who relapsed after initial treatment with PegIFN/RBV.

In this double-blind, randomized, placebo-controlled trial, 288 treatment-experienced GT-1 HCV patients were randomized (2:1:1) to receive either:

  • BI 201335 240mg QD with a three-day LI of PegIFN/RBV;
  • BI 201335 240mg QD plus PegIFN/RBV without LI; or
  • BI 201335 240mg twice-daily (BID) with a three-day LI of PegIFN/RBV

  • In each group, patients were given BI 201335 for 24 weeks in combination with PegIFN/RBV, which was given for 24 or 48 weeks.

    Patients in the two BI 201335 QD groups who achieved eRVR were re-randomized to either stop all treatment at Week 24 or continue PegIFN/RBV until Week 48.

    Treatment Outcomes in SILEN-C2 (Treatment-Experienced Patients)240mg
    QD/LI
    (N=142)240mg
    QD
    (N=76)240mg
    BID/LI
    (N=70)eRVR, %

    43

    45

    47Overall SVR, %

    28

    41

    31Breakthrough*, %

    25

    28

    17Relapse**, %

    25

    9

    19*Rebound on treatment with BI 20133
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
    7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
    10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
    11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... , Sept. 30, 2014 Aileron ... Summary Global Markets Direct,s, ,Aileron Therapeutics, ... an overview of the Aileron Therapeutics, Inc.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
    (Date:9/30/2014)... -- According to their CEO, Rob Bohacs ... going through a complete transformation with highly targeted ... current clinical trial management process isn,t configured to ... which will ultimately drive the prescription cancer drugs ... been recognized by the National Cancer Institute as an ...
    (Date:9/30/2014)... LOS ANGELES , Sept. 30, 2014   ... apnea shopping destination , today announced that it now ... ResMed . AirSense CPAPs are the first sleep apnea ... makes it simple and easy to track and share ... the overall effectiveness of their CPAP therapy.  In addition, ...
    Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
    ... Dec. 6, 2011 Talyst, a leader in ... American Society of Health-System Pharmacists (ASHP) Midyear Clinical ... access and secure management of CII medications. AutoVault ... restocking of controlled substance inventory. AutoVault ...
    ... The report " Active Pharmaceutical Ingredient (API) Market ... analyzes and studies the major market drivers, restraints, and opportunities ... Rest of the world. Browse market ... Pharmaceutical Ingredient (API) Market Trends, Competitive Landscape and Global Forecasts ...
    Cached Medicine Technology:Talyst Unveils AutoVault™ at ASHP 2011 2MarketsandMarkets: API Market is Expected to Reach $159.08 Billion by 2016 2MarketsandMarkets: API Market is Expected to Reach $159.08 Billion by 2016 3
    (Date:9/30/2014)... Irvine, Calif., Sept. 30, 2014 Research by UC ... system functions, shedding light on a vital process that ... , In the online version of Nature Immunology ... Zhou and other Institute for Immunology colleagues describe a ... and released into the bloodstream. , A T cell ...
    (Date:9/30/2014)... University of Maryland-led research team has been awarded ... Institutes of Health (NIH) to develop new imaging ... our understanding of how large networks of neurons ... This knowledge will help researchers identify the precise ... behavior, like decision-making and speaking, and alterations in ...
    (Date:9/30/2014)... September 30, 2014 EverStryke , the ... introduction to SurvivalLife.com along with a free book and class ... of Shane Michaels, prompting an investigative review. , “Joe ... in the survival and preparation niche, and this product is ... great classes and survival products that Joe offers on his ...
    (Date:9/30/2014)... 2014 Elevate , the latest product ... in and out of the gym by providing natural ingredients ... attention of Shane Michaels, prompting an investigative review. , ... reason most people simply just don’t have the ability to ... at work, getting the motivation to finish a project, or ...
    (Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... plastic surgery providers in Turkey has gone up more ... of growth. The medical tourism company also reported total ... since October 2012. , The company’s professional strategy has ... in Turkey — ultimately designed for patient comfort and ...
    Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
    ... researchers have found that yo-yo dieting can more than double ... dieting, also known as weight cycling, is a repeated loss ... ,Researchers studied 140,057 women aged between 50 and ... yo-yo dieting and compared women average waist size to those ...
    ... have found that symptoms in patients with obstructive sleep ... with nasal insufflation (TNI), using a nasal cannula ... rate. ,Our findings provide evidence that TNI ... obstructive hypopneas and apneas, said lead researcher Hartmut Schneider, ...
    ... Patients with Chronic Obstructive Pulmonary Disease (COPD) are increasingly ... disease , but a new study finds that the ... be hospitalized for pneumonia. ,In a large ... inhaled corticosteroid use was associated with a significant 70 ...
    ... to open FatBurger fast food joint in Miami, Florida . ... South Beach diner revealed that she has been hooked to ... college. ,"That was part of my L.A. education ... all these low-riders (cars)... FatBurger was, like, the centrepiece for ...
    ... flowing in two of China's longest rivers -- the Yangtze ... change linked to the contraction of wetlands, warned the ... at the Chinese Academy of Sciences (CAS) as saying after ... wetlands on the Tibetan Plateau had shrunk by over 10 ...
    ... Actor/comedian Eddie Murphy is the worlds biggest love-rat, according to ... who has been named by Mel Bs pal Victoria Beckham ... callous way after she got pregnant with his child, topped ... Nutty Professor actor insisted on a DNA test to prove ...
    Cached Medicine News:Health News:Nasal Cannula Treatment for Sleep Apnea Patients 2Health News:Nasal Cannula Treatment for Sleep Apnea Patients 3Health News:Patients Taking Inhaled Steroids may Develop Pneumonia 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: